We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?
Read MoreHide Full Article
ADMA Biologics (ADMA - Free Report) is witnessing a phenomenal run this year. Its shares have skyrocketed 320.6% year to date against the industry’s decline of 7.4%. The stock has also outperformed the sector and the S&P 500 during the aforementioned period.
ADMA has recently hit a new 52-week high of $23.64 on Nov. 11. The stock fell 19% since then and is currently trading at $19.01.
The stupendous rally can be attributed to the company’s consistently strong quarterly performance and increased guidance.
ADMA Outperforms Industry, Sector & S&P 500
Image Source: Zacks Investment Research
Asceniv’s Performance Fuels ADMA’s Growth
ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
The company’s top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin [“IVIG”] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).
Asceniv is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body’s immune system to neutralize microbes, such as bacteria and viruses, and prevent infection and disease. Asceniv is indicated for the treatment of PIDD or inborn errors of immunity in adults and adolescents. It is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company’s proprietary microneutralization assay.
Total revenues in the third quarter jumped 78% due to increased sales of Asceniv and third-party plasma sales by ADMA’s BioCenters business segment.
ADMA’s Efforts to Expand Asceniv’s Label
In connection with the FDA’s approval of Asceniv in April 2019, ADMA is required to conduct a pediatric study to evaluate the safety and efficacy of Asceniv in children and adolescents. The ongoing post-marketing study for Asceniv may provide a label expansion opportunity to include pediatric-aged PI patients.
All pediatric patients in Asceniv’s post-marketing pediatric study have now successfully completed their treatment schedule, and the clinical trial database is on track to be locked in the fourth quarter of 2024.
ADMA expects to file its supplemental biologics license application (sBLA) over the coming quarters, with a potential approval for label expansion in the first half of 2026. A potential label expansion will strengthen ADMA’s product portfolio.
ADMA’s Financial Targets
While reporting third-quarter results, ADMA raised its outlook for 2024 and 2025 yet again. ADMA now expects to generate revenues of more than $415 million in 2024 and $465 million in 2025 (previous guidance: more than $400 million in 2024 and $445 million in 2025). Net income is projected to exceed $120 million in 2024 and $165 million in 2025 (up from the prior guidance of $105 million for 2024 and $155 million for 2025).
Margin Improvement
ADMA’s higher-margin product portfolio now accounts for more than 50% of its total revenues. The company is working to increase Asceniv's supply. If successful, Asceniv will account for a significant portion of ADMA's total revenues over time, further advancing its potential margin expansion and earnings growth.
Valuation & Estimates
Going by the price/sales ratio, ADMA’s shares currently trade at 9.19x forward sales, higher than its mean of 3.46x and the industry’s 1.72x.
Image Source: Zacks Investment Research
The bottom-line estimate for 2024 earnings per share has increased 3 cents to 52 cents over the past 60 days, and the same for 2025 has jumped 14 cents.
Image Source: Zacks Investment Research
Conclusion
ADMA Biologics, which competes with Takeda (TAK - Free Report) and Grifols (GRFS - Free Report) in the U.S. market for plasma-derived products, is poised to perform well in the upcoming quarters. Incremental additional penetration of Asceniv should accelerate near-term revenue growth.
The targeted market has significant potential. Management expects additional opportunities for ADMA to continue to grow substantially in the underserved, immune-compromised and co-morbid patient population despite the availability of standard-of-care therapy.
Large biotech companies are generally considered safe havens for investors interested in this sector. Despite the exceptional rally this year, the stock will likely grow further, given the investors’ confidence in its prospects. Hence, any dip can be used as a buying opportunity.
For investors already owning the stock, staying invested would be a prudent move.
Image: Bigstock
ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?
ADMA Biologics (ADMA - Free Report) is witnessing a phenomenal run this year. Its shares have skyrocketed 320.6% year to date against the industry’s decline of 7.4%. The stock has also outperformed the sector and the S&P 500 during the aforementioned period.
ADMA has recently hit a new 52-week high of $23.64 on Nov. 11. The stock fell 19% since then and is currently trading at $19.01.
The stupendous rally can be attributed to the company’s consistently strong quarterly performance and increased guidance.
ADMA Outperforms Industry, Sector & S&P 500
Image Source: Zacks Investment Research
Asceniv’s Performance Fuels ADMA’s Growth
ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
The company’s top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin [“IVIG”] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).
Asceniv is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body’s immune system to neutralize microbes, such as bacteria and viruses, and prevent infection and disease. Asceniv is indicated for the treatment of PIDD or inborn errors of immunity in adults and adolescents. It is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company’s proprietary microneutralization assay.
Total revenues in the third quarter jumped 78% due to increased sales of Asceniv and third-party plasma sales by ADMA’s BioCenters business segment.
ADMA’s Efforts to Expand Asceniv’s Label
In connection with the FDA’s approval of Asceniv in April 2019, ADMA is required to conduct a pediatric study to evaluate the safety and efficacy of Asceniv in children and adolescents. The ongoing post-marketing study for Asceniv may provide a label expansion opportunity to include pediatric-aged PI patients.
All pediatric patients in Asceniv’s post-marketing pediatric study have now successfully completed their treatment schedule, and the clinical trial database is on track to be locked in the fourth quarter of 2024.
ADMA expects to file its supplemental biologics license application (sBLA) over the coming quarters, with a potential approval for label expansion in the first half of 2026. A potential label expansion will strengthen ADMA’s product portfolio.
ADMA’s Financial Targets
While reporting third-quarter results, ADMA raised its outlook for 2024 and 2025 yet again. ADMA now expects to generate revenues of more than $415 million in 2024 and $465 million in 2025 (previous guidance: more than $400 million in 2024 and $445 million in 2025). Net income is projected to exceed $120 million in 2024 and $165 million in 2025 (up from the prior guidance of $105 million for 2024 and $155 million for 2025).
Margin Improvement
ADMA’s higher-margin product portfolio now accounts for more than 50% of its total revenues. The company is working to increase Asceniv's supply. If successful, Asceniv will account for a significant portion of ADMA's total revenues over time, further advancing its potential margin expansion and earnings growth.
Valuation & Estimates
Going by the price/sales ratio, ADMA’s shares currently trade at 9.19x forward sales, higher than its mean of 3.46x and the industry’s 1.72x.
Image Source: Zacks Investment Research
The bottom-line estimate for 2024 earnings per share has increased 3 cents to 52 cents over the past 60 days, and the same for 2025 has jumped 14 cents.
Image Source: Zacks Investment Research
Conclusion
ADMA Biologics, which competes with Takeda (TAK - Free Report) and Grifols (GRFS - Free Report) in the U.S. market for plasma-derived products, is poised to perform well in the upcoming quarters. Incremental additional penetration of Asceniv should accelerate near-term revenue growth.
The targeted market has significant potential. Management expects additional opportunities for ADMA to continue to grow substantially in the underserved, immune-compromised and co-morbid patient population despite the availability of standard-of-care therapy.
Large biotech companies are generally considered safe havens for investors interested in this sector. Despite the exceptional rally this year, the stock will likely grow further, given the investors’ confidence in its prospects. Hence, any dip can be used as a buying opportunity.
For investors already owning the stock, staying invested would be a prudent move.
ADMA currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.